Literature DB >> 14638510

Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci.

Friedrich Kutscha-Lissberg1, Ute Hebler, Gert Muhr, Manfred Köller.   

Abstract

Penetration of linezolid into bone and joint tissues was studied by high-performance liquid chromatography in 13 patients suffering from implant-associated infections with methicillin-resistant staphylococci. Mean concentrations of linezolid in infected tissues were greater than 10 mg/liter in a sampling time range of 35 to 124 min after administration of the preoperative dose, except in bone specimens, where they reached 3.9 +/- 2.0 mg/liter.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14638510      PMCID： PMC296177          DOI： 10.1128/AAC.47.12.3964-3966.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Determination of linezolid in human serum and urine by high-performance liquid chromatography.

Authors:  K Borner; E Borner; H Lode
Journal:  Int J Antimicrob Agents       Date:  2001-09       Impact factor: 5.283

2.  Pharmacokinetics and tissue penetration of linezolid following multiple oral doses.

Authors:  T Gee; R Ellis; G Marshall; J Andrews; J Ashby; R Wise
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement.

Authors:  A M Lovering; J Zhang; G C Bannister; B J A Lankester; J H M Brown; G Narendra; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2002-07       Impact factor: 5.790

Review 4.  Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit.

Authors:  A S Haddadin; S A Fappiano; P A Lipsett
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

5.  Linezolid penetration into osteo-articular tissues.

Authors:  B Rana; I Butcher; P Grigoris; C Murnaghan; R A Seaton; C M Tobin
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

6.  Linezolid absolute bioavailability and the effect of food on oral bioavailability.

Authors:  I R Welshman; T A Sisson; G L Jungbluth; D J Stalker; N K Hopkins
Journal:  Biopharm Drug Dispos       Date:  2001-04       Impact factor: 1.627

Review 7.  Linezolid--a new option for treating gram-positive infections.

Authors:  D H Batts
Journal:  Oncology (Williston Park)       Date:  2000-08       Impact factor: 2.990

8.  Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.

Authors:  Dennis L Stevens; Daniel Herr; Harry Lampiris; John Lee Hunt; Donald H Batts; Barry Hafkin
Journal:  Clin Infect Dis       Date:  2002-05-13       Impact factor: 9.079

9.  A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum.

Authors:  C M Tobin; J Sunderland; L O White; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

Review 10.  Linezolid--a review of the first oxazolidinone.

Authors:  R Norrby
Journal:  Expert Opin Pharmacother       Date:  2001-02       Impact factor: 3.889
  10 in total
  21 in total

1.  Localized mandibular infection affects remote in vivo bioreactor bone generation.

Authors:  Emma Watson; Brandon T Smith; Mollie M Smoak; Alexander M Tatara; Sarita R Shah; Hannah A Pearce; Katie J Hogan; Jonathan Shum; James C Melville; Issa A Hanna; Nagi Demian; Joseph C Wenke; George N Bennett; Jeroen J J P van den Beucken; John A Jansen; Mark E Wong; Antonios G Mikos
Journal:  Biomaterials       Date:  2020-06-23       Impact factor: 12.479

2.  Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.

Authors:  Cornelia Buerger; Nele Plock; Pejman Dehghanyar; Christian Joukhadar; Charlotte Kloft
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Distribution of Linezolid in Tuberculosis Lesions in Patients with Spinal Multidrug-Resistant Tuberculosis.

Authors:  Yuan Li; Weijie Dong; Tinglong Lan; Jun Fan; Shibing Qin; Ai Guo
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 4.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

5.  Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant.

Authors:  J Gómez; E Canovas; V Baños; L Martínez; E García; A Hernández-Torres; M Canteras; J Ruiz; M Medina; P Martínez; A Canovas; A Soriano; M Clavel
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

6.  Osteointegration of poly(L: -lactic acid)PLLA and poly(L: -lactic acid)PLLA/poly(ethylene oxide)PEO implants in rat tibiae.

Authors:  Débora Cristina Coraça; Eliana Aparaecida R Duek; Carlos A Padovani; José Angelo Camilli
Journal:  J Mater Sci Mater Med       Date:  2008-02-19       Impact factor: 3.896

Review 7.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Clinical management of septic arthritis.

Authors:  Katie A Sharff; Eric P Richards; John M Townes
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.592

9.  Community-associated methicillin-resistant Staphylococcus aureus: incidence, clinical presentation, and treatment decisions.

Authors:  Fredrick M Abrahamian; Eric W Snyder
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

Review 10.  Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.

Authors:  Claire Roger; Jason A Roberts; Laurent Muller
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.